Advertisement
Document › Details
Proteintech Group, Inc.. (10/20/20). "Press Release: Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools". Chicago, IL & Munich.
Organisation | Proteintech Group Inc. | |
Group | Proteintech (Group) | |
Organisation 2 | ChromoTek GmbH | |
Group | Proteintech (Group) | |
Product | nanobody (general, camelid antibody) | |
Product 2 | research antibody | |
Index term | ChromoTek–Proteintech: investment, 202010 acquisition of ChromoTek by Proteintech Group | |
Person | Jung, Marion (T-Curx 202402– COO before ChromoTek Managing Director + Co-Founder + Earlybird Ventures) | |
Person 2 | Li, Jason (Proteintech 202010 CEO) | |
Proteintech, the benchmark in antibodies, today announces the acquisition of ChromoTek, a manufacturer of Camelid, single-domain antibodies, also known as nanobodies.
ChromoTek is the market leader in nanobodies — high-performance recombinant reagents used for breakthrough research discoveries. The combined companies will better address the industry’s growing opportunities and challenges in single cell analysis, super resolution imaging, and multiplex assays.
“Our fit-for-purpose nanobody-based tools perfectly complement the comprehensive antibody coverage of the proteome that Proteintech offers,” said Dr. Marion Jung, CEO of ChromoTek. “It is exciting to be working together with a company that shares our common values in reproducibility and quality for the benefit of research and beyond.”
Dr. Jason Li, CEO of Proteintech said, “This new partnership will deliver considerable value to the market. With global manufacturing across three continents, not only will we serve the research market better, but we’ll also deeply impact translational science and therapeutic applications.”
About Proteintech Group
Proteintech, founded in 2002, is a leading manufacturer of antibodies, proteins and immunoassays. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. With over 70,000 publications and confirmed specificity, Proteintech offers antibodies and immunoassays across research areas. In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. Proteintech sites are ISO13485 and ISO9001-2015 accredited. To learn more about Proteintech, please visit www.ptglab.com.
About ChromoTek
ChromoTek is a pioneer in the development and commercialization of innovative reagents based on camelid Nanobodies. In contrast to traditional antibodies, Nanobodies consist of only one single polypeptide chain; they are the smallest known antibodies. The company has a unique experience in the development of Nanobodies with desired affinities, specificities, and formats for dedicated applications in biomedical research where other antibody formats fail. As a market and product leader for high performing reagents, we are proud contributing to breakthrough research discoveries around the world. In addition, ChromoTek is a trusted service provider of custom-made Nanobodies for the pharmaceutical industry. Founded in 2008, ChromoTek has offices in Martinsried (Germany) near Munich and Islandia (NY, USA).
Contacts
Thompson + Conard Communications
Jane Thompson
jane@thompsonconard.com
1-415-710-1675
Record changed: 2023-06-05 |
Advertisement
More documents for Proteintech (Group)
- [1] T-Curx GmbH. (2/9/24). "Press Release: T-Curx Extends Its Management Team with Marion Jung, PhD, as Its New Chief Operating Officer"....
- [2] Cellbox Solutions GmbH. (9/20/21). "Press Release: Cellbox Solutions Establishes Subsidiary in the USA". Hamburg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top